1Early Breast Cancer TriallistsCo-operative Group（EBCTCG）.Systemic treatment of early breast by hormonal，cytotoxic，orimmunotherapy.Lancet，1992，339：1～15，71～85
2Miller WR.Endocrine treatment for breast cancers：biological rationale currentprogress.J Steroid Biochem Mol Biol，1990，37：467～80
3Howell A，DeFriend D，Robertson J，et al.Response to a specific antioestrogen（ICI182780）intamoxifen-resistant breast cancer.Lancet，1995，345：29～30
4Chander SK，Newton C，McCague R，et al.Pyrrolodie-4-iodotamoxifen，newanalogues of the antioestrogen tamoxifen for the treatment of breast cancer.Cancer Res，1991，51：5851～8
5WaKeling AE，Dukes M，Bowler J.A potent specific pure antioestrogen with clinicalpotential.Cancer Res，1991，51：3867～73
7DeFriend DJ，Anderson E，Bell J，et al.Effects of 4-hydroxytamoxifen and a pureantioestrogen（ICI 182780）on the clonogenic growth of human breast cancer cells invitro.Br J Cancer，1994，70：204～11
8Hayes DF，VanZyl JA，Hacking A，et al.Randomized comparison of tamoxifen and twoseparate doses of toremifene in postmenopausal patients with metastatic breast cancer.JClin Oncol，1995，13：2556～66
9Buzdar A，Jonat W，Howell A，et al.Anastrozole，a potent and selectivearomatase inhibitor，versus megestrol acetate in postmenopausal women with advancedbreast cancer：results of overview analysis of two phase Ⅲ trials.J Clin Oncol，1996，14：2000～11
10Suzder A，Jonat W，Howell A，et al.Significant improved survival with arimidex（anastrozole）versusmegestrol acetate in postmenopausal advanced breast cancer：updated results of tworandomized trials.Proc Am Soc Clin Oncol，1997，16：156
